AlphaRx Completes Flexogan Marketing Registration in Canada.Business Editors RICHMOND HILL, Ontario--(BW HealthWire)--Jan. 8, 2002 AlphaRx Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AHRX) announced today that it has completed the Canadian marketing registration of Flexogan(TM), a series of over-the-counter pain relieving products using the Company's proprietary (BCD (Binary Coded Decimal) The storage of numbers in which each decimal digit is converted into binary and is stored in a single character or byte. For example, a 12-digit number would take 12 bytes. See binary numbers. ) Bioadhesive Colloidal colloidal of the nature of a colloid. colloidal bath a bath containing gelatin, bran, starch or similar substances, to relieve skin irritation and pruritus. Dispersion(TM) Drug Delivery Technology. Flexogan is probably the most potent topical analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs available without a prescription in North America. Flexogan formulations suppress induced inflammation several times more effectively than currently marketed topical NSAID NSAID: see nonsteroidal anti-inflammatory drug. products, based on a non-infective inflammatory carrageenan car·ra·geen·an or car·ra·geen·in n. Any of a group of closely related colloids derived from several red algae, widely used as a thickening, stabilizing, emulsifying, or suspending agent in pharmaceuticals. experimental model. U.S. over-the-counter systemic analgesic market sales are estimated to be US$2.6 billion, prescription systemic analgesics US$3 billion and over-the-counter topical analgesics US$260 million for 2000. The Company believes that the U.S. topical analgesic market has the potential to grow to 3-4 times its' current levels with an effective product such as Flexogan. AlphaRx is currently in discussions with several world pharmas for the U.S. and/or European marketing rights to Flexogan. "We are very excited about Flexogan and its' remarkable effectiveness. Consumers now have a choice in the relief of minor arthritis and muscular pain with an effective topical product which eliminates the serious gastrointestinal side effects associated with oral analgesics." said Mr. Michael Lee, President of AlphaRx. Approximately 22 million people are diagnosed annually with rheumatoid arthritis and osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. in the United States. AlphaRx is targeting the 34 million Americans who take over-the-counter pain relievers for their arthritis. About AlphaRx AlphaRx is engaged in the development of novel formulations of drugs that are insoluble or poorly soluble in water. AlphaRx's broad product pipeline consists of carefully selected, mainly currently marketed drugs which, through the application of its proprietary BCD drug delivery systems, offer improved medical benefits over existing products as well as strong commercial potential. FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion